Article info

Download PDFPDF

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study

Authors

  1. Correspondence to Dr Sudha Visvanathan, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA; sudha.visvanathan{at}boehringer-ingelheim.com
View Full Text

Citation

Visvanathan S, Daniluk S, Ptaszyński R, et al
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study

Publication history

  • Received November 8, 2018
  • Revised February 20, 2019
  • Accepted February 24, 2019
  • First published March 22, 2019.
Online issue publication 
May 14, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.